ATE383430T1 - Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren - Google Patents
Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumorenInfo
- Publication number
- ATE383430T1 ATE383430T1 AT98912977T AT98912977T ATE383430T1 AT E383430 T1 ATE383430 T1 AT E383430T1 AT 98912977 T AT98912977 T AT 98912977T AT 98912977 T AT98912977 T AT 98912977T AT E383430 T1 ATE383430 T1 AT E383430T1
- Authority
- AT
- Austria
- Prior art keywords
- tumors
- recombinant antibodies
- bearing cells
- immune conjugates
- conjugates targeted
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4143797P | 1997-03-20 | 1997-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE383430T1 true ATE383430T1 (de) | 2008-01-15 |
Family
ID=21916511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98912977T ATE383430T1 (de) | 1997-03-20 | 1998-03-19 | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7541034B1 (enExample) |
| EP (1) | EP0970227B1 (enExample) |
| JP (3) | JP2002501488A (enExample) |
| AT (1) | ATE383430T1 (enExample) |
| AU (1) | AU740904B2 (enExample) |
| CA (1) | CA2284665C (enExample) |
| DE (1) | DE69838979T2 (enExample) |
| ES (1) | ES2300122T3 (enExample) |
| WO (1) | WO1998041641A1 (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0970227B1 (en) | 1997-03-20 | 2008-01-09 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors |
| US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| JP3835827B2 (ja) | 1997-05-02 | 2006-10-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンティッド バイ ザ セクレタリーオブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 悪性細胞に対する、ｏｎｃタンパク質を含む、免疫毒素 |
| US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| JP2004512262A (ja) | 2000-06-20 | 2004-04-22 | アイデック ファーマスーティカルズ コーポレイション | 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ |
| KR20030055274A (ko) | 2000-10-20 | 2003-07-02 | 츄가이 세이야꾸 가부시키가이샤 | 저분자화 트롬보포에틴 아고니스트 항체 |
| US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| DE60236450D1 (de) * | 2001-09-26 | 2010-07-01 | Us Health | Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen |
| TWI379693B (en) * | 2002-05-02 | 2012-12-21 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| JP2004279086A (ja) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | 放射線画像変換パネル及び放射線画像変換パネルの製造方法 |
| EP2204385A1 (en) | 2003-11-25 | 2010-07-07 | The Government Of U.S.A, As Represented By Secretary, Department of Health and Human Sevices | Pseudomonas exotoxin A mutants and uses thereof |
| WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
| US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
| EP1880027B1 (en) | 2005-05-02 | 2014-02-19 | Cold Spring Harbor Laboratory | Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster |
| EP1908482B1 (en) | 2005-06-10 | 2017-09-06 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
| CN101262885B (zh) | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
| NZ591252A (en) * | 2006-03-17 | 2012-06-29 | Biogen Idec Inc | Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| US8591889B2 (en) | 2008-04-04 | 2013-11-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies specific for CD22 |
| US9238878B2 (en) | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
| WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| AU2010292069B2 (en) | 2009-09-11 | 2015-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Improved Pseudomonas Exotoxin A with reduced immunogenicity |
| EP3797847A1 (en) | 2010-07-30 | 2021-03-31 | Medlmmune, LLC | Purified active polypeptides or immunoconjugates |
| RU2606016C2 (ru) | 2011-01-14 | 2017-01-10 | Редвуд Байосайнс, Инк. | Меченые альдегидом полипептиды иммуноглобулина и способы их применения |
| AU2012228100B2 (en) | 2011-03-17 | 2016-09-08 | The University Of Birmingham | Re-directed immunotherapy |
| JP6100764B2 (ja) | 2011-06-09 | 2017-03-22 | アメリカ合衆国 | 免疫原性の低いｔ細胞及び／又はｂ細胞エピトープを有するシュードモナス外毒素ａ |
| US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
| ES2656505T3 (es) | 2011-09-16 | 2018-02-27 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Exotoxina A de Pseudomonas con epítopos de linfocitos B menos inmunogénicos |
| JP6267644B2 (ja) | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗ｃｄ２２キメラ抗原受容体 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| CA2878642C (en) * | 2012-07-19 | 2020-12-22 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
| US9920124B2 (en) | 2012-12-20 | 2018-03-20 | Medimmune, Llc | Methods of producing immunoconjugates |
| WO2014205187A1 (en) | 2013-06-20 | 2014-12-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor |
| MX382731B (es) | 2013-09-27 | 2025-03-13 | Chugai Pharmaceutical Co Ltd | Metodo para producir heteromultimeros de polipeptidos. |
| RU2687143C2 (ru) | 2013-10-06 | 2019-05-07 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Модифицированный экзотоксин а псевдомонад |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| CN107427590B (zh) | 2015-02-02 | 2021-08-31 | 伯明翰大学 | 具有多个t细胞表位的靶向部分肽表位复合物 |
| WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
| KR102673972B1 (ko) | 2015-05-30 | 2024-06-10 | 몰레큘러 템플레이츠, 인코퍼레이션. | 탈면역된 시가 독소 a 서브유닛 스캐폴드 및 이를 포함하는 세포-표적화 분자 |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| AU2016354009B2 (en) | 2015-11-09 | 2021-05-20 | R.P. Scherer Technologies, Llc | Anti-CD22 antibody-maytansine conjugates and methods of use thereof |
| PT3377103T (pt) | 2015-11-19 | 2021-05-26 | Revitope Ltd | Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas |
| WO2017115773A1 (ja) | 2015-12-28 | 2017-07-06 | 中外製薬株式会社 | Ｆｃ領域含有ポリペプチドの精製を効率化するための方法 |
| CN109071634A (zh) | 2016-04-26 | 2018-12-21 | R.P.谢勒技术有限责任公司 | 抗体偶联物及其制备和使用方法 |
| US11795235B2 (en) | 2017-09-18 | 2023-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotoxins with albumin binding domain |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| US20230212286A1 (en) | 2020-06-01 | 2023-07-06 | Innobation Bio Co., Ltd. | Antibodies specific for cd22 and uses thereof |
| WO2022008688A1 (en) | 2020-07-10 | 2022-01-13 | F. Hoffmann-La Roche Ag | Antibodies which bind to cancer cells and target radionuclides to said cells |
| CN115210262B (zh) * | 2020-09-29 | 2023-07-14 | 昆明赛诺制药股份有限公司 | 人源化抗-cd22重组免疫毒素及其应用 |
| KR102393776B1 (ko) | 2020-12-30 | 2022-05-04 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체 |
| KR20230137900A (ko) | 2020-12-31 | 2023-10-05 | 사나 바이오테크놀로지, 인크. | Car-t 활성을 조정하기 위한 방법 및 조성물 |
| JP2024503027A (ja) | 2021-01-11 | 2024-01-24 | サナ バイオテクノロジー，インコーポレイテッド | Ｃｄ８標的ウイルスベクターの使用方法 |
| CA3204291A1 (en) | 2021-01-13 | 2022-07-21 | F. Hoffmann-La Roche Ag | Combination therapy |
| JP2024511424A (ja) | 2021-03-25 | 2024-03-13 | ダイナミキュア バイオテクノロジー エルエルシー | 抗ｉｇｆｂｐ７構築物およびその使用 |
| WO2022246293A1 (en) | 2021-05-19 | 2022-11-24 | Sana Biotechnology, Inc. | Hypoimmunogenic rhd negative primary t cells |
| IL308097A (en) | 2021-05-27 | 2023-12-01 | Sana Biotechnology Inc | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
| US20240316198A1 (en) | 2021-07-14 | 2024-09-26 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
| WO2023015217A1 (en) | 2021-08-04 | 2023-02-09 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| EP4384598A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| AU2022325232A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
| WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| WO2023019225A2 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| EP4384188A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
| EP4419117A1 (en) | 2021-10-22 | 2024-08-28 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
| US20240408192A1 (en) | 2021-12-17 | 2024-12-12 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| WO2023115039A2 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| EP4473097A1 (en) | 2022-02-02 | 2024-12-11 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| CA3244101A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | MODIFIED CD47 PROTEINS AND THEIR USES |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024097314A2 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Methods and systems for determining donor cell features and formulating cell therapy products based on cell features |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024220560A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| WO2024220574A1 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| WO2024220598A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
| WO2024243340A1 (en) | 2023-05-23 | 2024-11-28 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025043172A1 (en) | 2023-08-23 | 2025-02-27 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
| WO2025054202A1 (en) | 2023-09-05 | 2025-03-13 | Sana Biotechnology, Inc. | Method of screening a sample comprising a transgene with a unique barcode |
| WO2025096757A1 (en) | 2023-11-01 | 2025-05-08 | Sana Biotechnology, Inc. | Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas |
| US20250230470A1 (en) | 2024-01-12 | 2025-07-17 | Sana Biotechnology, Inc. | Safety switches to control in vitro and in vivo proliferation of cell therapy products |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56145222A (en) * | 1980-04-28 | 1981-11-11 | Toshiyuki Hamaoka | Improved antibody and its preparation |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US5476659A (en) | 1982-11-09 | 1995-12-19 | The Scripps Research Institute | Cancerous B cell treatment using substituted nucleoside derivatives |
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US5045451A (en) | 1988-10-26 | 1991-09-03 | Board Of Regents | Methods for screening antibodies for use as immunotoxins |
| US5165923A (en) | 1989-11-20 | 1992-11-24 | Imperial Cancer Research Technology | Methods and compositions for the treatment of hodgkin's disease |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| US5591629A (en) * | 1994-04-29 | 1997-01-07 | Mayo Foundation For Medical Education & Research | Monoclonal antibodies which promote central nervous system remyelination |
| EP0970227B1 (en) * | 1997-03-20 | 2008-01-09 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant antibodies and immunoconjugates targeted to cd-22 bearing cells and tumors |
-
1998
- 1998-03-19 EP EP98912977A patent/EP0970227B1/en not_active Expired - Lifetime
- 1998-03-19 ES ES98912977T patent/ES2300122T3/es not_active Expired - Lifetime
- 1998-03-19 CA CA2284665A patent/CA2284665C/en not_active Expired - Lifetime
- 1998-03-19 DE DE69838979T patent/DE69838979T2/de not_active Expired - Lifetime
- 1998-03-19 US US09/381,497 patent/US7541034B1/en not_active Expired - Fee Related
- 1998-03-19 AT AT98912977T patent/ATE383430T1/de active
- 1998-03-19 WO PCT/US1998/005453 patent/WO1998041641A1/en not_active Ceased
- 1998-03-19 AU AU67646/98A patent/AU740904B2/en not_active Expired
- 1998-03-19 JP JP54081298A patent/JP2002501488A/ja not_active Withdrawn
-
2008
- 2008-03-18 JP JP2008070484A patent/JP2008208131A/ja active Pending
-
2009
- 2009-04-30 US US12/433,737 patent/US9592304B2/en not_active Expired - Fee Related
-
2010
- 2010-03-31 JP JP2010084519A patent/JP2010200752A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US7541034B1 (en) | 2009-06-02 |
| JP2008208131A (ja) | 2008-09-11 |
| DE69838979D1 (de) | 2008-02-21 |
| US20090305411A1 (en) | 2009-12-10 |
| JP2002501488A (ja) | 2002-01-15 |
| US9592304B2 (en) | 2017-03-14 |
| EP0970227A1 (en) | 2000-01-12 |
| AU6764698A (en) | 1998-10-12 |
| JP2010200752A (ja) | 2010-09-16 |
| DE69838979T2 (de) | 2008-12-24 |
| EP0970227B1 (en) | 2008-01-09 |
| CA2284665C (en) | 2010-08-17 |
| ES2300122T3 (es) | 2008-06-01 |
| WO1998041641A1 (en) | 1998-09-24 |
| AU740904B2 (en) | 2001-11-15 |
| CA2284665A1 (en) | 1998-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE383430T1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
| EP1071460A4 (en) | INTERNALIZING ERB2 ANTIBODIES | |
| DE69910216D1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
| ATE365562T1 (de) | Zielgerichtete kombinations-immuntherapie für krebs | |
| BR0209862A (pt) | Imunoconjugados de anticorpos de cd44 citotóxicos | |
| ATE296105T1 (de) | Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel | |
| CY1119291T1 (el) | Πολυσθενη αντισωματα και χρησεις για αυτα | |
| TR200003161T2 (tr) | Poliol-IFN-Beta konjugatları | |
| BR0209254A (pt) | anticorpos de bloqueio cripto e usos dos mesmos | |
| BRPI0012196B8 (pt) | artigo industrializado | |
| DK1180123T3 (da) | Immunkonjugater, der har höj bindingsaffinitet | |
| ATE470714T1 (de) | Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen | |
| ATE463505T1 (de) | Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren | |
| IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
| NZ334828A (en) | Contains no O-acetyl groups detectable by NMR and binds to antibodies to S.aureus further conjugated with Pseudomonas aeruginosa exotoxin A as an immunocarrier to detect S.aureus infection | |
| DE3789587D1 (de) | Rekombinantes Pseudomonastoxin : Konstruktion eines wirksamen Immunotoxins mit wenigen Nebenwirkungen. | |
| ATE196314T1 (de) | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit | |
| WO1999004820A3 (en) | Cytolysis of target cells by superantigen conjugates inducing t-cell activation | |
| DK0845998T3 (da) | Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles | |
| RU92016354A (ru) | Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата | |
| DK0525119T3 (da) | Antistofkonjugater til behandling af neoplastisk sygdom | |
| ATE304709T1 (de) | Substanzen mit verzweigten linkermolekülen | |
| ATE527358T1 (de) | Ribosomen inaktivierendes protein vom typ-1 | |
| PT1107793E (pt) | Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados | |
| Maison et al. | Improved chemical strategies for the targeted therapy of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0970227 Country of ref document: EP |